Literature DB >> 23436751

Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.

Gesine Respondek1, Sigrun Roeber, Hans Kretzschmar, Claire Troakes, Safa Al-Sarraj, Ellen Gelpi, Carles Gaig, Wang Zheng Chiu, John C van Swieten, Wolfgang H Oertel, Günter U Höglinger.   

Abstract

Autopsy is the diagnostic gold standard for progressive supranuclear palsy (PSP). The National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of "probable" PSP are thought to possess high specificity and low sensitivity. The NINDS-SPSP criteria for "possible" PSP are considered to increase sensitivity at the expense of specificity. The Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) criteria are intended to improve sensitivity while maintaining high specificity. The aim of this study was to conduct a clinicopathological evaluation of the NINDS-SPSP and NNIPPS criteria in tertiary neurological centers. Defined clinical features and their year of onset were recorded by chart review in neuropathologically diagnosed patients with PSP, Parkinsons's disease (PD), MSA parkinsonism and corticobasal degeneration from four European brain banks. Fulfillment of the clinical diagnostic criteria was verified for each year after disease onset and for the final antemortem record. We analyzed 98 PSP patients and 46 disease controls. The NINDS-SPSP "probable" criteria yielded shorter time to diagnosis, slightly higher specificity and positive predictive value (PPV), and similar sensitivity, compared with the NNIPPS criteria. Unexpectedly, the NINDS-SPSP "possible" criteria yielded the lowest sensitivity, specificity, and PPV. A combination of NINDS-SPSP possible and probable criteria yielded the highest sensitivity. We suggest that the NINDS-SPSP probable criteria might be preferred for recruitment of patients for clinical trials, where an early and specific diagnosis is important. For routine clinical care, where high sensitivity is crucial, a combination of NINDS possible and probable criteria might be preferred.
Copyright © 2013 Movement Disorder Society.

Entities:  

Mesh:

Year:  2013        PMID: 23436751     DOI: 10.1002/mds.25327

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  53 in total

1.  LRP10 variants in progressive supranuclear palsy.

Authors:  Leonie J M Vergouw; Shamiram Melhem; Laura Donker Kaat; Wang Z Chiu; Demy J S Kuipers; Guido Breedveld; Agnita J W Boon; Li-San Wang; Adam C Naj; Elizabeth Mlynarksi; Laura Cantwell; Marialuisa Quadri; Owen A Ross; Dennis W Dickson; Gerard D Schellenberg; John C van Swieten; Vincenzo Bonifati; Frank Jan de Jong
Journal:  Neurobiol Aging       Date:  2020-04-30       Impact factor: 4.673

Review 2.  Hearing and music in dementia.

Authors:  Julene K Johnson; Maggie L Chow
Journal:  Handb Clin Neurol       Date:  2015

3.  Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia.

Authors:  Christopher Kobylecki; Matthew Jones; Jennifer C Thompson; Anna M Richardson; David Neary; David M A Mann; Julie S Snowden; Alexander Gerhard
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

4.  MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism.

Authors:  V C Constantinides; G P Paraskevas; G Velonakis; P Toulas; E Stamboulis; E Kapaki
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-05       Impact factor: 3.825

5.  Adaptive semantic tag mining from heterogeneous clinical research texts.

Authors:  T Hao; C Weng
Journal:  Methods Inf Med       Date:  2014-10-20       Impact factor: 2.176

Review 6.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

7.  MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Christopher G Schwarz; Hugo Botha; Matthew L Senjem; Anthony J Spychalla; J Eric Ahlskog; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Mov Disord       Date:  2018-11-23       Impact factor: 10.338

8.  A test for Creutzfeldt-Jakob disease using nasal brushings.

Authors:  Christina D Orrú; Matilde Bongianni; Giovanni Tonoli; Sergio Ferrari; Andrew G Hughson; Bradley R Groveman; Michele Fiorini; Maurizio Pocchiari; Salvatore Monaco; Byron Caughey; Gianluigi Zanusso
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

9.  The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage.

Authors:  Han Soo Yoo; Seok Jong Chung; Soo-Jong Kim; Jung Su Oh; Jae Seung Kim; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-04       Impact factor: 9.236

Review 10.  The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.